TY - JOUR
T1 - Migraine
T2 - disease characterisation, biomarkers, and precision medicine
AU - Ashina, Messoud
AU - Terwindt, Gisela M.
AU - Al-Karagholi, Mohammad Al Mahdi
AU - de Boer, Irene
AU - Lee, Mi Ji
AU - Hay, Debbie L.
AU - Schulte, Laura H.
AU - Hadjikhani, Nouchine
AU - Sinclair, Alexandra J.
AU - Ashina, Håkan
AU - Schwedt, Todd J.
AU - Goadsby, Peter J.
N1 - Funding Information:
MA is a consultant, speaker or scientific advisor for AbbVie, Allergan, Amgen, Alder, Biohaven, Eli Lilly, Lundbeck, Novartis, and Teva, and primary investigator for Alder, Amgen, Allergan, Eli Lilly, Lundbeck, Novartis and Teva trials. MA has no ownership interest and does not own stocks of any pharmaceutical company. MA serves as associate editor of Cephalalgia, and associate editor of the Journal of Headache and Pain. MA is president of the International Headache Society. GMT reports grants or consultancy support from Novartis, Lilly, Teva, and Allergan, and independent support from the Dutch Research Council, National Institutes of Health, European Community, Dutch Heart Foundation, and Dutch Brain Foundation. MA-MA-K has acted as an invited speaker for Novartis and received a travel grant from ElectroCore. MJL reports grants from the National Research Foundation of Korea, Korean Society of Neurosonology, and Yuhan Company. MJL is also a consultant, speaker or scientific advisor for Eli Lilly and has received speaker honoraria from Sanofi-Aventis and YuYu Pharma, outside the submitted work. MJL serves as junior editor of Cephalalgia. DLH reports grants from the Royal Society of New Zealand (Marsden Fund), Living Cell Technologies, and the Maurice Wilkins Centre, during the conduct of the study. DLH is a consultant, speaker or scientific advisor for Eli Lilly, Intarcia Therapeutics, Merck Sharp & Dohme, and Amgen–Novartis, outside the submitted work. DLH serves as an editor of the British Journal of Pharmacology. LHS has received speaker honoraria from Allergan, outside the submitted work. AJS reports grants from Sir Jules Thorn Award for Biomedical Research, during the conduct of the study. AJS reports personal and speaker fees for a single lecture in 2019 from Novartis, and received funding for a 12-month clinical headache fellowship at the Department of Neurology, Queen Elizabeth Hospital (Birmingham, UK). AJS is also funded by Allergan and reports personal fees from participation on advisory boards for Novartis and Allergan, outside the submitted work. TJS reports personal fees from Alder, Allergan, Abbvie, Amgen, Biohaven, Cipla, Click Therapeutics, Dr Reddys, Eli Lilly, Equinox, Ipsen, Lundbeck, Novartis, Teva, Weber and Weber, and XoC, research grants from the American Migraine Foundation, Amgen, Henry Jackson Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, and US Department of Defense. TLS also reports stock options from Aural Analytics and Nocira, and royalties from UpToDate, outside the submitted work. PJG reports, over the last 36 months, grants and personal fees from Amgen and Eli-Lilly, grants from Celgene, and personal fees from Alder Biopharmaceuticals, Aeon Biopharma, Allergan, Biohaven Pharmaceuticals, Clexio, Electrocore, eNeura, Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, MundiPharma, Novartis, Pfizer, Praxis, Sanofi, Santara Therapeutics, Satsuma, Teva Pharmaceuticals, Trigemina, and WL Gore, and personal fees for advice through the Gerson Lehrman Group, LEK and Guidepoint, fees for educational materials from the Massachusetts Medical Society, Medery, Medlink, PrimeEd, UptoDate, and WebMD, and publishing royalties from Oxford University Press and Wolters Kluwer, and for medicolegal advice in headache, and a patent on magnetic stimulation for headache (number WO2016090333 A1) assigned to eNeura without fee. All other authors declare no competing interests.
Publisher Copyright:
© 2021 Elsevier Ltd
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4/17
Y1 - 2021/4/17
N2 - Migraine is a disabling neurological disorder, diagnosis of which is based on clinical criteria. A shortcoming of these criteria is that they do not fully capture the heterogeneity of migraine, including the underlying genetic and neurobiological factors. This complexity has generated momentum for biomarker research to improve disease characterisation and identify novel drug targets. In this Series paper, we present the progress that has been made in the search for biomarkers of migraine within genetics, provocation modelling, biochemistry, and neuroimaging research. Additionally, we outline challenges and future directions for each biomarker modality. We also discuss the advances made in combining and integrating data from multiple biomarker modalities. These efforts contribute to developing precision medicine that can be applied to future patients with migraine.
AB - Migraine is a disabling neurological disorder, diagnosis of which is based on clinical criteria. A shortcoming of these criteria is that they do not fully capture the heterogeneity of migraine, including the underlying genetic and neurobiological factors. This complexity has generated momentum for biomarker research to improve disease characterisation and identify novel drug targets. In this Series paper, we present the progress that has been made in the search for biomarkers of migraine within genetics, provocation modelling, biochemistry, and neuroimaging research. Additionally, we outline challenges and future directions for each biomarker modality. We also discuss the advances made in combining and integrating data from multiple biomarker modalities. These efforts contribute to developing precision medicine that can be applied to future patients with migraine.
UR - https://www.scopus.com/pages/publications/85103935054
U2 - 10.1016/S0140-6736(20)32162-0
DO - 10.1016/S0140-6736(20)32162-0
M3 - Review article
C2 - 33773610
AN - SCOPUS:85103935054
SN - 0140-6736
VL - 397
SP - 1496
EP - 1504
JO - The Lancet
JF - The Lancet
IS - 10283
ER -